Boss's Boss

$XL2CSOPHYNIX(07709.HK) Did a quick day trade before the close. Dinner money is covered. However, I currently judge that 7709 has entered a short-term uptrend, so I'll hold my 2,200 shares and stay put. Will reassess by Friday's close.

$NVIDIA(NVDA.US) Thanks to NVDA. It saved the AI bubble and reinforced it. We can keep blowing it up for a while longer 😄

$Tesla(TSLA.US) bought at the open. Also picked up $Rocket Lab(RKLB.US). The current level feels comfortable. Aiming to hold long-term.

$XL2CSOPHYNIX(07709.HK) Queuing for fill, pretty good. Ups and downs, the money for meals is very stable.

$XTALPI(02228.HK)

Based on the aforementioned in-depth research, we present a clear core conclusion:

The current timing calls for [maintaining positions] (and adding to positions at dips during volatile pullbacks / optimizing portfolio structure), rather than systematically reducing exposure.

The Hong Kong innovative medicine sector has completed industrial clearing and undergone a fundamental qualitative shift, entering a golden window period of advancing from historically extremely low valuations to an earnings-driven upward cycle. The core supporting logic for this judgment is as follows:

1. Valuation is at an absolute bottom; downside risk is locked in (high payoff ratio)

The valuation discount for Hong Kong biopharma assets has reached extreme historical levels. Currently, the price-to-sales ratio (PS-TTM) for Hang Seng Tech and related biotech assets is approximately 2.3x, and the P/E ratio (PE-TTM) is around 20x, both sitting in the bottom 10% of their five-year historical percentiles. Current secondary market prices have already priced in extreme pessimism regarding geopolitical frictions and macro liquidity disturbances. The risk of further significant compression in valuations is very limited, providing a solid margin of safety.

2. Industry fundamentals have crossed the break-even line; endogenous cash-generating capability is established (high certainty)

In contrast to the past phase of relying on external financing to "burn cash and paint pie charts," leading Chinese innovative drug companies have fully entered a "period of earnings realization" supported by actual sales revenue and cash flow:

Alright, AI has found me reasons to hold. I'll close my eyes and ignore XtalPi, shifting my attention back to the great crypto circle $iShares Bitcoin Trust ETF(IBIT.US) $IShares Ethereum Trust ETF(ETHA.US)

$XTALPI(02228.HK) Honestly, I'm running out of patience. What should I do? Feeling a bit frustrated...

$GREEN TEA GROUP(06831.HK) Mark, earnings report released today. Green Tea has the potential to become the No. 1 Chinese restaurant chain brand in China. Fully self-operated, with initial store opening costs recovered in approximately 13 months.

Last night, I had the opportunity to meet the founder of Green Tea, who came to Hong Kong to release the earnings report. He gave me a lesson. This company is quite interesting.

$Alibaba(BABA.US) is out of the water, and caramel popcorn is waving at me! Oh my god! It's Saturday.

$Recursion Pharmaceuticals(RXRX.US) always reminds me of the 'little rocket' from back in the day. It's been consolidating around $3 for a while now—is a reversal finally here?

$XL2CSOPHYNIX(07709.HK) bought back all 500 shares before the close; high probability of a short-term upward consolidation.

$UNITREE(688836.SH) Given this company's R&D investment and its consistent attitude towards R&D, the target price should be 10 RMB

$XTALPI(02228.HK) This trend today is just bullying! It's blatantly bullying! The helplessness of retail investors!

$Rocket Lab(RKLB.US)@周树人的交易员 is swapping XtalPi for 'Little Rocket'. Is now a good time? What's your gut feeling?

$XTALPI(02228.HK) Every lot is 10,000 shares. Just playing around, at 7709 today I didn't do it. tnnd

$XTALPI(02228.HK) seems like the market today is trying to ride the coattails, as $Recursion Pharmaceuticals(RXRX.US) already did last night. Let's wait and see. Overall, looking at the 'big toy' company that just listed on the A-share market yesterday, there's little reason for optimism. I hope the A-shares can stage a big rally soon to rescue consumer spending.

I originally hoped Qingtai could spin a compelling narrative in these areas, but it appears management may be constrained by contracts and unable to do so. Ultimately, their position in the ecosystem is simply too peripheral.

Looking at that 'big toy' company listing on the A-shares yesterday, all I can do is sigh. Capital is finite; once it flows into the 'big toys,' it won't be available for other ventures like Changsheng Bulao.

$IShares Ethereum Trust ETF(ETHA.US) it's picking up! The biggest surprise! Hodler!

$Alibaba(BABA.US) Small bets are fun! Qwen has delivered results this round. Let's see if there's a chance to visit the earnings release venue tomorrow.$BABA 260821 135 Call(BABA260821C135000.US) Bought 5 contracts

$Rocket Lab(RKLB.US)$XTALPI(02228.HK) tough break for both. Hurts like hell, really hurts.

$Roundhill Memory ETF(DRAM.US) Such volatility really puts me in a tough spot. Adding to my position blindly invites criticism, and I have to endure the pain; not adding to it will likely result in extreme distress anyway, unless I want to stay away from storage stocks entirely.

I need to strengthen my faith.

$XL2CSOPHYNIX(07709.HK) A triumphant escape, really. I have to admire our neighbors in the northeast; I've even bought their phone as my main entertainment device.

$SK Hynix(SKHY.US) Yesterday afternoon, followed by a chaotic seven-injuries punch this morning, I currently hold 3,500 shares at an average price of 34.15. Playing with Koreans is just that thrilling.

$SK Hynix(SKHY.US) Dived deep underwater, then suddenly surfaced again. This is truly a gamble. Watch your leverage carefully; staying alive is the most important thing.

$XTALPI(02228.HK) Technically broke support again. Awkward... Waiting for the post-market earnings report. If there are real issues, I may need to consider partial position rotation. The time cost is too high.

$Roundhill Memory ETF(DRAM.US) added a total of 1,800 shares in the pre-market today. Total holdings are now 2,888 shares, with a cost basis around $57.3, the current price.